What Prescription Drugs are in Your Future?
Reuters, the news service, published a list of prescription drugs that are predicted to likely to be the top sellers in 2014. For comparison purposes, the forecasts for the top sellers predicted for 2010 were also included.
|
|
Projected Sales 2010 |
||
|
Rank |
Brand (Indication) |
Company |
Sales ($bln) |
|
1 |
Lipitor (cholesterol) |
Pfizer |
11.7 |
|
2 |
Plavix (clotting) |
Sanofi Aventis |
9.6 |
|
3 |
Advair(asthma-COPD) |
GSK |
9.0 |
|
4 |
Remicade (arthritis) |
J&J |
7.4 |
|
5 |
Enbrel (arthritis) |
Pfizer |
7.0 |
|
6 |
Humira (arthritis) |
Abbott |
6.8 |
|
7 |
Avastin (cancer) |
Roche |
6.7 |
|
8 |
Rituxan (cancer) |
Roche |
6.1 |
|
9 |
Diovan (hypertension) |
Novartis |
6.0 |
|
10 |
Crestor (cholesterol) |
AstraZeneca |
5.8 |
|
Projected Sales 2014 |
|||
|
Rank |
Brand (Indication) |
Company |
Sales ($bln) |
|
1 |
Avastin (cancer) |
Roche |
8.9 |
|
2 |
Humira (arthritis) |
Abbott |
8.5 |
|
3 |
Enbrel (arthritis) |
Pfizer |
8.0 |
|
4 |
Crestor (cholesterol) |
AstraZeneca |
7.7 |
|
5 |
Remicade (arthritis) |
J&J |
7.6 |
|
6 |
Rituxan (cancer) |
Roche |
7.4 |
|
7 |
Lantus (diabetes) |
Sanofi Aventis |
7.1 |
|
8 |
Advair(asthma-COPD) |
GSK |
6.8 |
|
9 |
Herceptin (cancer) |
Roche |
6.4 |
|
10 |
Novolog (diabetes) |
Novo Nordisk |
5.7 |
A quick perusal of the list suggests that there will likely be a shift toward the use of injected biologics in 2014 as compared with orally bioavailable small molecule drugs.
This should come as no surprise since most major pharmaceutical companies have publicly announced that biologics and biotechnology drugs are the key to their future successes.
Until next time
Good Luck and Good Job Hunting!!!!!
It has been a long time coming, but legislation reforming the US healthcare system will likely be realized in 2010. While the law will likely be passed in 2010, many of its provisions and actionable items won’t be enacted until 2014 (at least in the current bill). I hope that negotiations between the House and Senate change the start date and that the law takes effect in 2010.
It is amazing the things you learn if you pay attention from time to time. While attending a meeting on e-healthcare last week in Philadelphia I learned that according to the American public the pharmaceutical industry is less popular than the banking industry. This was startling to me given that the recent financial collapse was caused almost entirely by the banking industry. That the pharmaceutical industry is more reviled than the banking industry suggests that life sciences company have a bit of PR work to do. But, not to worry, people still hate the oil industry more than the pharmaceutical industry.